U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

GC822-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/581,106 Filing Date **September 10, 2007** INFORMATION DISCLOSURE First Named Inventor Judith A. Fox STATEMENT BY APPLICANT Art Unit 1643 (Use as many sheets as necessary) **Examiner Name Alana Harris Dent**

Attorney Docket Number

2

Sheet

1

U.S.PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (if known})			Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS						
	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	В1	WO 02/28862	04/11/2002	Emory University		
	B2	WO 03/008451	01/30/2003	Universitat Zurich		
	 -					

$\overline{}$		
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	Complete if Known		
Substitute for form 1443B/LTO	Application Number	10/581,106	
INFORMATION DISCLOSURE	Filing Date	September 10, 2007	
STATEMENT BY APPLICANT	First Named Inventor	Judith A. Fox	
(Use as many sheets as necessary)	Art Unit	1643	
	Examiner Name	Alana Harris Dent	
Sheet 2 of 2	Attorney Docket Number	GC822US	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т	
	C1	Bhatia, J., et al., "Catalytic Activity of an <i>In Vivo</i> Tumor Targeted Anti-CEA scFv::Carboxypeptidase G2 Fusion Protein." <i>Int. J. Cancer</i> 85: 571-577, 2000		
	C2	Goshorn, S.C., et al., "Genetic Construction, Expression, and Characterization of a Single Chain Anti-Carcinoma Antibody Fused to β-Lactamase." <i>Cancer Research</i> 53: 2123-2127, 1993		
	C3	Michael, N.P., et al., "In vitro and in vivo characterization of a recombinant carboxypeptidase G ₂ ::anti-CEA scFv fusion protein." <i>Immunotechnology</i> 2: 47-57, 1996		
			_	
Examiner Signature		Date Considered		

oighaid.	Considered
·	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Dra	raw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant.	

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.